Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Amgen's stock plunges after early trial data suggests its weight loss drug, MariTide, may decrease bone density.

flag Amgen's stock dropped over 7% after data from an early-stage trial of its experimental weight loss drug, MariTide, showed a potential 4% decrease in bone mineral density over 12 weeks. flag While some analysts see this as a safety risk, others argue it's an overreaction and call for more data. flag MariTide aims to be taken monthly, unlike weekly treatments from competitors. flag Wall Street awaits phase two trial results expected by year-end.

14 Articles

Further Reading